United Therapeutics shares were on the rise after the company announced positive results from a Phase III trial of Viveta, an inhaled version of pulmonary arterial hypertension (PAH) drug Remodulin. Patients taking Viveta were able to walk farther in six minutes than those taking placebo. Analysts expect United to file an NDA sometime in June. If approved, Viveta will compete with Actelion's Ventavis, the only other inhaled PAH drug on the market.
- read the AP report